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OBJECTIVES The purpose of this study was to examine the two-year clinical outcomes in patients enrolled
in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study.
BACKGROUND The SIRIUS study was a double-blinded randomized study which demonstrated that
sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and
clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS).
METHODS Patients with de novo native coronary artery lesions randomized to either SES (533 patients)
or control BMS (525 patients) were followed for two years.
RESULTS Between one and two years, there were infrequent additional clinical events that were equally
distributed between the sirolimus and control groups. After two years, target lesion
revascularization was 5.8% and 21.3% in SES and control patients, respectively (p  0.001),
and major adverse cardiovascular events and target vessel failure rates were 10.1% versus
24.4% and 12.0% versus 26.7%, respectively (p 0.0001 for both). There were no differences
in death, myocardial infarction, and stent thrombosis between the two groups.
CONCLUSIONS Clinical outcomes two years after implantation of SES continue to demonstrate significant
reduction in the need for repeat target lesion (and vessel) revascularization compared with
BMS without evidence for either disproportionate late restenosis or late stent
thrombosis. (J Am Coll Cardiol 2006;47:1350–5) © 2006 by the American College of





















cn multiple blinded randomized clinical trials, drug-eluting
tents (containing sirolimus or paclitaxel) have shown sig-
ificant improvement in angiographic and clinical outcomes
ompared with bare-metal stents (BMS) (1–9). However,
here are sparse data supporting the long-term benefits of
See page 1361
rug-eluting stents in patients with coronary lesions beyond
he first year after stent implantation (10,11). The
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Manuscript received January 9, 2005; revised manuscript received October 28,
005, accepted November 7, 2005.irolimus-Eluting Stent in De Novo Native Coronary
esions (SIRIUS) multicenter blinded randomized trial
xamined the safety and efficacy of sirolimus-eluting stents
SES) in 1,058 patients, and results up to one year indicated
ignificant reduction in both restenosis and target lesion
evascularization (TLR) (2,3). This report extends the
linical follow-up of the original SIRIUS patient cohort to
etermine if the early and middle-term safety and efficacy of
ES is maintained at two years.
ETHODS
tudy design and eligibility criteria. The methods of the
IRIUS trial were previously reported (2). Patients enrolled
n the study had a clinical history of angina and single
oronary target lesions, 15 to 30 mm in length, in vessels 2.5
o 3.5 mm in diameter. Major exclusion criteria included
ecent myocardial infarction, left ventricular ejection frac-
ion 25%, target lesion in an ostial or bifurcation location,
r a thrombotic or severely calcified lesion.
ata collection and follow-up. Patients had clinical eval-
ations at 30 days and 6, 9, 12, and 24 months. Two-year
linical follow-up was supervised by the physician investi-
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April 4, 2006:1350–5 The SIRIUS Trial: Two-Year Follow-Upites. Patients were queried by telephone interview, and in
he case of clinical events, source medical documents were
etrieved and reviewed and adjudicated by an independent
linical Events Committee blinded to the treatment assign-
ent. Complete data compliance for all two-year follow-up
nd points was 91.6% for the BMS group and 92.3% for the
ES group.
tudy end points. This two-year follow-up study focuses
n clinical restenosis or TLR, defined as the need for
linically driven repeat percutaneous intervention of the
arget lesion or bypass surgery of the target vessel. Clinical
ndications for repeat revascularizations included a positive
oninvasive functional study, ischemic electrocardiogram
hanges at rest in a distribution consistent with the target
essel, or ischemic symptoms and an in-lesion diameter
tenosis by quantitative coronary angiography of 50%. In
ddition, in the absence of the aforementioned objective
riteria for ischemia, an in-lesion diameter stenosis by
uantitative coronary angiography of 70% was also con-
idered of sufficient severity to justify repeat revasculariza-
ion. The independent Clinical Events Committee blindly
djudicated all clinically driven revascularization episodes.
he SIRIUS secondary clinical end points included non-
LR target vessel revascularization (TVR), target vessel
ailure (TVF), and major adverse cardiac events (MACE).
he definitions of these end points have been previously
escribed (2).
Early stent thrombosis, either acute (within 24 h) or
ubacute (between 24 h and 30 days), was defined as
ngiographic documentation of target vessel occlusion or
ny death or myocardial infarction occurring within 30 days
hat is not clearly related to causes other than stent occlu-
ion. The protocol definition of late stent thrombosis was
yocardial infarction occurring 30 days after the index
rocedure and attributable to the target vessel, angiographic
ocumentation (site-reported or by quantitative coronary
ngiography) of thrombus or total occlusion of the target
ite, and freedom from an interim revascularization of the
arget vessel. This very stringent definition represents defi-
ite late stent thrombosis. For the purposes of this report,
e have extended the definition of late stent thrombosis to
nclude additional categories of possible and cannot exclude
Abbreviations and Acronyms
BMS  bare-metal stents
LAD  left anterior descending coronary artery
MACE  major adverse cardiac event
PES  paclitaxel-eluting stents
SES  sirolimus-eluting stents
SIRIUS  Sirolimus-Eluting Stent in De Novo Native
Coronary Lesions
TLR  target lesion revascularization
TVF  target vessel failure
TVR  target vessel revascularizationate stent thrombosis. The definition of possible late stent shrombosis includes patients with myocardial infarction
ccurring 30 days after the index procedure and attribut-
ble to the target vessel, no identifiable “culprit” lesion
lsewhere, and freedom from an interim revascularization of
he target vessel. The definition of cannot exclude late stent
hrombosis includes patients with sudden cardiac death30
ays after the index procedure, no identifiable “culprit”
esion elsewhere (as suggested by nontarget vessel electro-
ardiogram changes or autopsy evidence of a patent target
essel), and freedom from interim TVR.
tatistical analysis. The effectiveness analysis and the
afety evaluation were performed on a modified intent-to-
reat population; de-registered patients were not included in
he analysis because they received neither study treatment.
Continuous variables are summarized as means and
tandard deviations and compared between treatment
roups using t test. Categorical variables are summarized as
requencies and percentages and compared between treat-
ent groups using the Fisher exact test. Out-of-hospital
utcomes are summarized as Kaplan-Meier event rates and
ompared between treatment groups using log-rank tests.
ll tests are two-sided with a significance level of 0.05.
ultivariate predictors were identified by using a Cox
odel with an entry/stay criteria of 0.10/0.15. All statistical
nalyses were performed with SAS software (version 6.12;
AS Institute, Cary, North Carolina).
ESULTS
s previously reported, both groups had similar baseline
linical and angiographic characteristics, procedural factors,
nd acute (in-hospital) results (2).
ong-term clinical outcomes. At two years, the signifi-
ant differences between the SES and BMS groups in TLR,
VR, TVF, and MACE were all maintained (Table 1, Fig.
). There were small increases in both groups and still no
ifferences in death or myocardial infarction. The specific
tiologies of all-cause mortality between one and two years,
ncluded cardiac deaths in two patients (chest pain followed
y cardiac arrest, one case in each group) and noncardiac
eaths in five patients (one case of documented noncardiac
udden death in the SES group, two deaths due to severe
hronic lung disease in the SES group, and two deaths due
o malignancy in the control group). There were infrequent
ate TLR events in both groups between one and two years
0.9% for SES and 1.3% for control stents), and the
agnitude of reduction in clinical restenosis was the same at
ne and two years (TLR 5.8% for SES group and 21.3% for
ontrols at two years; p  0.001).
Various higher restenosis-risk patient and lesion sub-
roups (including diabetes, left anterior descending coro-
ary artery [LAD] lesion location, small vessel size, and
ong lesion length) were examined by univariate analysis
Fig. 2). In all cases, the significant reduction in TLR
ssociated with SES compared with BMS controls in these
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The SIRIUS Trial: Two-Year Follow-Up April 4, 2006:1350–5redicted TLR at two years were evaluated using multiple
ogistic regression analysis in the entire study group and in
he SES group alone. In the entire study group, indepen-
ent predictors of TLR included assignment to sirolimus
reatment (hazard ratio [HR] 0.21; p  0.001), reference
essel diameter (HR 0.55; p  0.02), diabetes mellitus (HR
.56; p  0.03), LAD location (HR 1.06; p  0.03), and
otal stent length (relative 3% increase in risk for each 1-mm
ncrease in stent length; p  0.0001).
Stent thrombosis episodes (definite, possible, and cannot
xclude) were distributed into early events (up to 30 days
fter the index procedure), late events up to 1 year, and late
vents between 1 and 2 years for both the SES and the
ontrol patients (Table 2). Early stent thrombosis and





(n  525) p Value
ll events at 1 year
Death 7 (1.3) 4 (0.8) 0.547
Cardiac 3 (0.5) 2 (0.4) 1.000
Non-cardiac 4 (0.8) 2 (0.4) 0.678
MI (all) 16 (3.0) 18 (3.4) 0.730
Q-wave 4 (0.8) 2 (0.4) 0.687
Non–Q-wave 12 (2.3) 16 (3.0) 0.449
TLR (clinically driven) 26 (4.9) 105 (20.0) 0.0001
TL CABG 5 (0.9) 9 (1.7) 0.295
TL PCI 23 (4.3) 101 (19.2) 0.0001
TVR (non-TLR) 19 (3.6) 35 (6.7) 0.025
MACE 44 (8.3) 117 (22.3) 0.001
TVF 52 (9.8) 24.8 (130) 0.0001
ll events at 2 years
Death 11 (2.1) 7 (1.3) 0.477
Cardiac 4 (0.8) 3 (0.6) 1.000
Non-cardiac 7 (1.3) 4 (0.8) 0.547
MI (all) 22 (4.1) 25 (4.8) 0.656
Q-wave 6 (1.1) 5 (1.0) 1.000
Non-Q-wave 17 (3.2) 20 (3.8) 0.618
TLR (clinically driven) 31 (5.8) 112 (21.3) 0.0001
TL CABG 6 (1.1) 13 (2.5) 0.110
TL PCI 28 (5.3) 108 (20.6) 0.0001
TVR (non-TLR) 26 (4.9) 38 (7.2) 0.122
MACE 55 (10.3) 132 (25.1) 0.0001
TVF 64 (12.0) 140 (26.7) 0.0001
ll events between 1 and 2 years
Death 4 (0.8) 3 (0.6) 1.000
Cardiac 1 (0.2) 1 (0.2) 1.000
Non-cardiac 3 (0.6) 2 (0.4) 1.000
MI (all) 6 (1.1) 7 (1.3) 1.000
Q-wave 2 (0.4) 3 (0.6) 1.000
Non-Q-wave 5 (0.9) 4 (0.8) 1.000
TLR (clinically driven) 5 (0.9) 7 (1.3) 0.576
TL CABG 1 (0.2) 4 (0.8) 0.214
TL PCI 5 (0.9) 7 (1.3) 0.576
TVR (non-TLR) 7 (1.3) 3 (0.6) 0.342
MACE 11 (2.0) 15 (2.9) 0.433
TVF 12 (2.3) 10 (1.9) 0.830
alues are % (no. of cases). Events at 1 year were reported previously (15).
CS  control stent; MI  myocardial infarction; PCI  percutaneous coronary
ntervention; SES sirolimus-eluting stent; TL target lesion; TLR target lesion
evascularization; TVF  target vessel failure; TVR  target vessel revascularization.efinite late stent thrombosis up to one year was observed in two SES patients (0.4%) and in four control patients (0.8%).
efinite late stent thrombosis between one and two years
as seen in one additional SES patient and in no control
atients (overall definite stent thrombosis frequency up to
wo years was 0.6% for SES and 0.8% for control; nonsig-
ificant difference). Possible late stent thrombosis occurred
n no SES patients and in two control patients (one between
0 days and 1 year and one between 1 and 2 years). Cannot
xclude late stent thrombosis occurred in two SES patient
one between 30 days and 1 year and one between 1 and 2
ears) and in two control patients (one between 30 days and
year and one between 1 and 2 years). Overall cumulative
tent thrombosis (including all categories of late stent
hrombosis) up to two years after the index procedure
ccurred in five SES (0.9%) and in eight control BMS
atients (1.5%, p  0.11).
ISCUSSION
ver the past two years, since the introduction of drug-
luting stents into the U.S., there has been an evolving
hange in the treatment paradigm such that the vast
ajority of current patients receive SES or paclitaxel-
luting stents (PES) during percutaneous coronary interven-
ions. Studies examining angiographic, intravascular ultra-
ound, and clinical end points have demonstrated safety and
fficacy of these devices during the first year after therapy
1–9,12,13). Long-term follow-up after drug-eluting stent
mplantation is only available for small numbers of patients
ith focal uncomplicated lesion morphologies (10,11).
herefore, rigorous late clinical follow-up of the earliest
atient cohorts from large randomized clinical trials exposed
o drug-eluting stents becomes essential to ensure patient
afety and to determine if antirestenosis efficacy is main-
ained. The major findings of this two-year follow-up report
nvolving patients treated with SES from the SIRIUS trial
re: 1) clinical restenosis (with blinded adjudication of all
linically driven TLR events) shows maintained antirest-
nosis efficacy; and 2) late complications such as stent
hrombosis between one and two years were rare and
ccurred with similar frequency in SES and BMS groups.
The concern of late restenosis (after 6 to 12 months) with
otent antiproliferative therapies derives from experiences
ith intravascular radiation (vascular brachytherapy) which
as introduced for the prevention of recurrent in-stent reste-
osis. Despite the significant short-term efficacy of vascular
rachytherapy systems (14–18), long-term follow-up results
ave been less gratifying. A small series of patients with
erial angiography and intravascular ultrasound demon-
trated relatively early “catch-up” or delayed restenosis
manifested as increased late-loss lumen loss) between 6 and
2 months after beta-vascular brachytherapy (19). More
mportantly, the five-year follow-up of the gamma-vascular
rachytherapy Washington Radiation for In-Stent Reste-
osis Trial (WRIST) (in-stent restenosis patients) showed
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April 4, 2006:1350–5 The SIRIUS Trial: Two-Year Follow-Upntravascular radiation compared with placebo had four
imes greater late TLR (21.6% vs. 4.7%; p  0.04) (20).
his late “catch-up” or delayed restenosis phenomena has
lso been observed with some of the earlier drug-eluting
tents. In a small study involving in-stent restenosis pa-
ients, the QuaDS-QP2 stent (polymer sleeve eluting a
axane derivative, Quanam Medical Corp., Santa Clara,
alifornia) resulted in excellent reduction in restenosis at 6
onths, but marked deterioration in angiographic and
linical outcomes after 12-month evaluations (21). The
urrent analysis from the SIRIUS trial, the largest random-
igure 1. Kaplan-Meier event-free survival at two years for target lesion rev
ailure (TVF). p  0.001 for all comparisons of sirolimus-eluting stent (S
igure 2. Odds ratios for target lesion revascularization at 720 days for th
rm by subgroup. Bars represent odds ratio point estimates and 95% confidence
rtery.zed study (1,058 patients) treating patients with SES (2), is
articularly meaningful because there was no evidence of
isproportionate late clinical events with SES, including
eath, myocardial infarctions, stent thrombosis, and repeat
evascularizations after two-year follow-up (Table 1, Fig. 1).
A recent report (22) has raised concerns that PES and
ES may be associated with an increased frequency of late
tent thrombosis episodes, in the setting of cessation of
ntiplatelet therapy. A total of four patients (two with SES
nd two with PES) experienced late stent thrombosis (at
east six months after the index procedure), within days after
rization (TLR), major adverse coronary events (MACE), and target vessel
s. control bare-metal stent.
rall population and by subgroup. Values represent event rates (%) in eachasculae ove
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The SIRIUS Trial: Two-Year Follow-Up April 4, 2006:1350–5he cessation of all antiplatelet therapy (both aspirin and
lopidogrel). In three of these four patients, the thrombotic
pisodes were during or after surgical or endoscopic proce-
ures, and in two of the patients stent thrombosis was only
n the drug-eluting stent target vessel, whereas BMS in
ther vessels were confirmed to be patent. Based on these
oncerns, the SIRIUS patients were analyzed in far greater
etail employing an expanded definition of late stent throm-
osis to include those patients without angiographic docu-
entation of stent thrombus or occlusion and even in those
atients with unexplained sudden cardiac death (Table 2).
f note, dual antiplatelet therapy using aspirin and clopi-
ogrel was maintained for only three months in SIRIUS
atients, whereupon the aspirin was routinely continued and
he clopidogrel was stopped. Overall, we could not deter-
ine any differences in definite, possible, and cannot exclude
ate stent thrombosis (up to two years) when comparing the
ES and BMS treated patients. Cumulative overall stent
hrombosis using the less rigorous definitions was 0.9% in
ES patients and 1.5% in control patients (p  0.11).
nterestingly, there were two episodes of possible late stent
hrombosis that occurred in the BMS group, one soon after
essation of aspirin therapy in a woman anticipating a
cheduled elective hysterectomy (clopidogrel had already
een stopped months previously) and another during non-
ardiac surgery after both aspirin and clopidogrel had been
topped. Thus, although we recognize that late stent throm-
osis will continue to be a carefully scrutinized clinical com-
lication after drug-eluting stent implantation, especially in an
nvironment where more complex lesion subsets are being
reated, we cannot ascertain in the SIRIUS trial any differences
n overall and late stent thrombosis between SES and BMS.
onclusions. The maintained clinical safety and improved
fficacy at two years in SIRIUS patients should provide
ome confidence that late untoward events are unlikely to be
ssociated with SES. Nevertheless, the SIRIUS trial only
ncluded patients with intermediate lesion complexity, and
he results cannot be extrapolated to all patient subsets and
esion subgroups. Therefore, additional clinical data are
equired in more complex patients and lesions to make
ategorical statements about long-term safety and efficacy of
ES. Importantly, annual follow-up of the SIRIUS patients
ill continue for five years to provide further assurance that this
requently utilized and important interventional device fulfills
able 2. Stent Thrombosis (Up to Two Years’ Follow-Up)
Early
0–30 days 31–360 days
SES CS SES CS
efinite 1 (0.2%) 1 (0.2%) 1 (0.2%) 3 (0.6
ossible 0 0 0 1 (0.2
annot exclude 0 0 1 (0.2%) 1 (0.2
ll events 1 (0.2%) 1 (0.2%) 2 (0.4%) 5 (1.0
ee Methods section for the various categories of stent thrombosis (definite, possibl
Abbreviations as in Table 1.he most rigorous standards of long-term safety and efficacy.eprint requests and correspondence: Dr. Martin B. Leon,
enter for Interventional Vascular Therapy, Columbia University
edical Center, Herbert Irving Pavilion, 161 Fort Washington
venue, 5th Floor, New York, New York 10032. E-mail:
leon@crf.org.
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